Current Report Filing (8-k)
July 20 2021 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 19, 2021
|
INMUNE
BIO INC.
|
|
|
(Exact
name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
incorporation)
|
|
|
|
Identification
No.)
|
980
North Federal Highway, Suite 110
Boca
Raton, FL 33432
(Address
of Principal Executive Offices) (Zip Code)
(858)
964 3720
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per shares
|
|
INMB
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other
Events.
On
July 19, 2021, INmune Bio Inc., a Nevada corporation (the “Company”), issued a press release announcing that the
Company will present a poster at the Alzheimer’s Association International Congress 2021, which is being held in a hybrid format,
Denver and online, from July 26-30, 2021. In addition, Dr. Malu Tansey of the University of Florida College of Medicine and co-inventor
of XPro1595 (pegipanermin), will deliver a plenary talk, entitled, “Therapeutic Approaches Targeting Innate Immunity in
AD.” A copy of this press release is attached as Exhibit 99.1.
Item
9.01 Financial statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INMUNE
BIO INC.
|
|
|
Date:
July 20, 2021
|
By:
|
/s/
David Moss
|
|
|
David
Moss
|
|
|
Chief
Financial Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024